Trial Condition(s):

Bronchitis, Chronic

AVANTI - Avelox® in Acute exacerbations of chroNic bronchiTIs

Bayer Identifier:

14689

ClinicalTrials.gov Identifier:

NCT00846911

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events.

This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.

Inclusion Criteria
- Patients at least 35 years of age with a diagnosis of Acute Exacerbation of Chronic Bronchitis (AECB) and decision taken by the investigator to treat with Avelox.
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information.

Trial Summary

Enrollment Goal
2672
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Avelox (Moxifloxacin hydrochloride, BAY12-8039)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Russia

Status
Completed
 
Locations

Investigative Site

Many Locations, Moldova

Status
Completed
 
Locations

Investigative Site

Many Locations, Kazakhstan

Status
Completed
 
Locations

Investigative Site

Many Locations, Macedonia

Status
Completed
 
Locations

Investigative Site

Many Locations, Albania

Status
Completed
 
Locations

Investigative Site

Many Locations, Slovakia

Status
Completed
 
Locations

Investigative Site

Many Locations, Ukraine

Status
Completed
 
Locations

Investigative Site

Many Locations, Bosnia and Herzegovina

Status
Completed
 

Trial Design